title: Clinical expression of rheumatoid arthritis in Chilean patients.
abstract: In populations such as Northern Europeans in which the HLA-DR4 subtypes DW14 and Dw4 show strong association with rheumatoid arthritis (RA), these alleles and the double allelic dose of the shared epitope are considered severity markers. The clinical expression of RA varies in different populations, which may be determined by variation in the prevalence of these markers. In the present study we analyzed the expression of RA in 112 consecutive Chilean patients and its relation to the prevalence of genetic factors, prompted by our previous observation that DR4 is weakly associated to RA in this population. Mean age was 50 +/- 14 years; 90% were seropositive and 87% were female, with a disease duration of 10 +/- 8 years. Extra-articular manifestations were found in 38% of patients, rheumatoid nodules in 27%, vasculitis in 8%, and Sjogren's syndrome in 29%. Functional capacity (ACR, 1991) I or II: 82%.15% of patients stopped working. Hand radiographs scored according to Steinbrocker in 89 patients: I, 21%; II, 15%; III, 43%; IV, 21%. In this series, patients with less formal education seemed to have more benign arthritis. In 97 controls and in 65 (56%) RA patients the presence of DRB1 alleles corresponding to DR1 and DR4 serotypes, to DR4-Dw subtypes, and homozygocity, were determined by polymerase chain reaction followed by specific oligonucleotide hybridization. The shared epitope was present in 53% of RA patients and in 30% of controls (P = .0048, odds ratio [OR] = 2.64). A double allelic dose of the epitope was present in 15% of RA patients compared with 4% of controls (P = .026, OR = 4.23). In a subgroup of 31 erosive RA patients we did not find a significant association of disease severity with the shared epitope in a single or double allelic dose. None of the DR4 subtypes that associate with RA in other populations was found significantly more prevalent in our patients. The severity of RA in our study compared with published series was intermediate between British patients with severe RA and Greek patients with milder disease. This may be due to the high prevalence of Dwl3*0403 in our population.
authors.affiliation: Departamento de Immunologia Clinica y Reumatologia, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile.
authors.forename: L
authors.initials: L
authors.lastname: Massardo
authors.forename: V
authors.initials: V
authors.lastname: Aguirre
authors.forename: M E
authors.initials: ME
authors.lastname: García
authors.forename: V
authors.initials: V
authors.lastname: Cervila
authors.forename: S
authors.initials: S
authors.lastname: Nicovani
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: S
authors.initials: S
authors.lastname: Rivero
authors.forename: S
authors.initials: S
authors.lastname: Jacobelli
mesh_terms: D000328:Adult; D000367:Age Factors; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000453:epidemiology* / Q000276:immunology*; D002677:Chile / Q000453:epidemiology; D004522:Educational Status; D005260:Female; D006681:HLA-D Antigens / Q000097:blood; D015804:HLA-DR4 Antigen / Q000097:blood; D006650:Histocompatibility Testing; D006720:Homozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D012737:Sex Factors; D013997:Time Factors; D014937:Work
chemical_list: D006681:HLA-D Antigens; D015804:HLA-DR4 Antigen